Suzy Bibawy, MD
Adolescent Medicine · Staten Island, NYNPI 1982611125
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $496, 4.5 times the $111 reported in 2019.
Across 40 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Potrero Medical, Inc.$154
- Gilead$130
- Merck$107
- GSK$94
- Johnson & Johnson$57
- Lilly USA, LLC$48
- plus $349 from 13 others
What the payments were for
- Food & beverage$92498%
- Education$152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Potrero Medical, Inc. | 1 | $154 |
| Gilead | 7 | $130 |
| Merck | 7 | $107 |
| GSK | 5 | $94 |
| Johnson & Johnson | 2 | $57 |
| Lilly USA, LLC | 2 | $48 |
| Novartis | 2 | $45 |
| Pfizer | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Insulet Corporation | 1 | $29 |
| Vifor Pharma, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Exact Sciences | 1 | $21 |
| Viiv Healthcare Company | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
How this compares
$939 in reported general payments places this provider in the 75th percentile of 257 adolescent medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 118 | $107,250 |
| EntrestoSacubitril/Valsartan | 25 | $28,957 |
| OzempicSemaglutide | 20 | $25,910 |
| EliquisApixaban | 31 | $25,434 |
| FarxigaDapagliflozin Propanediol | 31 | $23,508 |
| JardianceEmpagliflozin | 20 | $22,175 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $15,743 |
| XareltoRivaroxaban | 18 | $15,545 |
| TradjentaLinagliptin | 14 | $9,802 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,110 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,538 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $5,648 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 177 | $4,648 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $4,604 |
| Arnuity ElliptaFluticasone Furoate | 19 | $4,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $107 | $122,993142 claims |
| NovartisEntresto | $45 | $28,95725 claims |
| PfizerEliquis | $42 | $25,43431 claims |
| AstraZenecaFarxiga | $20 | $23,50831 claims |
| Johnson & JohnsonXarelto | $57 | $15,54518 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $94 | $11,51736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 257 adolescent medicine providers in New York.
Other adolescent medicine in Staten Island
- Melanie GoldNew York$61K
- Jonathan JasseyRoslyn$31K
- Michelle Collins-OgleBronx$13K
- Katherine GreenbergRochester$9K
- Juan EspinozaBrentwood$8K
- Anne MosconaNew York$7K
- Chelikani VarmaDepew$6K
- Maureen CooneyNyack$6K
- Michael RosenbaumNew York$5K
- Joseph CalabroPoughkeepsie$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.